Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACMAN-Hu19
2023-507597-40-00Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MB-HUCART19.1 in acute lymphoblastic leukemia (ALL) and mature B-cell lymphoma, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Dose at which ≤ 1 patient experiences a dose limiting toxicity within 28 days after CAR T-cell infusion. Planned start Dec 2025; status: authorised.
02
Drugs
MB-HUCART19.1
03
Conditions
acute lymphoblastic leukemia (ALL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2023-507597-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507597-40-00.